PARLIAMENT QUESTION: HOMI BHABHA CANCER HOSPITALS AND RADIOPHARMACEUTICAL PRODUCTION CENTRES

1. At a Glance

• Homi Bhabha Cancer Hospitals (HBCH) are tertiary cancer-care facilities run by the Tata Memorial Centre (TMC), a Grant-in-Aid institution under the Department of Atomic Energy (DAE) [1][2].
• Radiopharmaceutical Production Centres are operated by BRIT (Board of Radiation and Isotope Technology), Mumbai, a constituent unit of DAE, supplying isotopes to 400+ nuclear medicine centres in India [3].
• Demonstrates the dual-use civilian dividend of India's nuclear programme — bridging GS-III (Science & Tech) with GS-II (Health governance).

2. Why in the News

• PIB / Parliament Question (04 Feb 2026) by DAE giving hospital-wise data on commissioning year, beds, patients registered (2025) and surgeries performed (2025) for Tata Memorial Hospital, ACTREC, MPMMCC Varanasi and HBCHs [1].
• PM inaugurated the 150-bed HBCH & Research Centre, Muzaffarpur (Bihar) on 22 August 2025 [2].
• DAE Year End Review 2025 highlighted radiopharmaceutical and cancer-care expansion [4].

3. Background & Evolution

• 1941 — Tata Memorial Hospital, Mumbai established (oldest cancer hospital in India) [1].
• 1962 — Administrative control of TMH transferred to DAE [general DAE history].
• 2002 — ACTREC (Advanced Centre for Treatment, Research and Education in Cancer), Navi Mumbai commissioned [1].
• 19 Feb 2019 — MPMMCC, Varanasi (Mahamana Pt. Madan Mohan Malaviya Cancer Centre) commissioned [1].
• 2018 — Cabinet approved DAE/TMC takeover of Dr. B. Borooah Cancer Institute, Guwahati [5].
• Aug 2022 — PM dedicated HBCH & Research Centre, Mohali (SAS Nagar) to the nation [6].
• Aug 2025 — HBCH Muzaffarpur (Bihar) inaugurated [2].

4. Core Static Facts

• Parent Ministry/Department: Department of Atomic Energy (under PMO, no Cabinet Minister) [1].
• Implementing apex body: Tata Memorial Centre (TMC), Mumbai — a Grant-in-Aid institute of DAE [2].
• Radiopharmaceutical producer: BRIT, Mumbai (constituent unit of DAE) [3].
• HBCH network locations cited by PIB/DAE: Varanasi, Mullanpur (Mohali, Punjab), Sangrur, Visakhapatnam, Muzaffarpur [2].
• Key isotopes produced via Dhruva reactor & medical cyclotron: Mo-99, I-125, I-131, Sm-153, Lu-177, F-18 [3].
• Distribution reach: 400+ nuclear medicine centres nationwide [3].
• Flagship indigenous teletherapy machine: Bhabhatron (BARC, transferred to industry) [4].
• Hospital data (2025) from PIB Feb 2026 reply [1]:
• Tata Memorial Hospital, Mumbai (1941) — 650 beds; 35,705 registered; 43,208 surgeries.
• ACTREC, Navi Mumbai (2002) — 500 beds; 8,970 registered; 12,588 surgeries.

• MPMMCC, Varanasi (19/02/2019) — 394 beds; 25,047 registered; 4,188 surgeries.

• HBCH Mullanpur (Punjab): 300-bed tertiary cancer hospital, built at ~₹660 crore [6].

• HBCH Muzaffarpur (Bihar): 150-bed, commissioned 22 Aug 2025 [2].
• Subsidy norm at TMC: ~60% patients (general category) receive free/highly subsidised care [2].

5. Multi-Dimensional Analysis

Scientific / Technological

• Reactor-based isotope production (Dhruva, Mumbai) + medical cyclotron for short-half-life PET isotopes (F-18) [3].
• BARC-developed Bhabhatron indigenous radiotherapy unit reduces import dependence on Co-60 teletherapy machines [4].
• Proton Therapy Facility at ACTREC, Kharghar — treated 500 patients within 2 years of inception [7].

Social / Equity

• Geographic decentralisation of cancer care into Tier-2/3 cities (Varanasi, Sangrur, Mohali, Muzaffarpur, Vizag) addresses catastrophic out-of-pocket health expenditure [2].
• 60% subsidised slot for general-category patients — strong pro-poor cross-subsidy model [2].

Administrative / Governance

• Unusual placement: a tertiary health network under DAE, not MoHFW — rooted in radiation oncology expertise of BARC; coordinated with Ayushman Bharat for tertiary referrals [4].
• TMC manages diverse acquired institutions (e.g., Dr. B. Borooah Cancer Institute, Guwahati) via Cabinet-approved takeovers [5].

Strategic / Self-Reliance

• Indigenous Lu-177 and Mo-99 production reduces reliance on global isotope supply (which faces chronic shortages) — aligns with Atmanirbhar Bharat in health-tech [3].

6. Recent Developments (last 12-18 months)

• 04 Feb 2026 — DAE tables hospital-wise 2025 patient & surgery data in Parliament [1].
• 22 Aug 2025 — HBCH & RC Muzaffarpur (150-bed) inaugurated by PM [2].
• 2025 — DAE Year End Review flags continued expansion of cancer hospital and radiopharma network [4].
• 2025 — Proton Therapy Facility at ACTREC crosses 500 patients milestone [7].
• 2025 — Parliament Q on shortage of medical radioisotopes addressed by DAE [S3 family / PRID 2153081].

7. Prelims Hooks

• TMC, Mumbai is a Grant-in-Aid institute of Department of Atomic Energy (NOT Ministry of Health) [2].
• Radiopharmaceuticals in India are produced by BRIT (Board of Radiation & Isotope Technology), Mumbai [3].
• Bhabhatron = indigenous teletherapy machine developed by BARC [4].
• Isotopes produced in Dhruva reactor (Trombay): Mo-99, I-125, I-131, Sm-153, Lu-177 [3].
• F-18 is produced via medical cyclotron, not reactor [3].
• ACTREC = Advanced Centre for Treatment, Research and Education in Cancer; Navi Mumbai; 2002 [1].
• MPMMCC (full form: Mahamana Pandit Madan Mohan Malaviya Cancer Centre) — Varanasi, commissioned 19 Feb 2019 [1].
• Dr. B. Borooah Cancer Institute, Guwahati was brought under TMC/DAE in 2018 [5].
• HBCH locations: Varanasi, Mullanpur (Mohali), Sangrur, Visakhapatnam, Muzaffarpur [2].
• HBCH Mullanpur: 300 beds, ~₹660 crore [6].
• BRIT supplies to 400+ nuclear medicine centres in India [3].
• DAE is under the Prime Minister's Office (no independent Cabinet Minister).

8. Mains Relevance

• GS-II: Issues relating to development & management of Social Sector — Health. Government policies for vulnerable sections.
• GS-III: Science & Technology — Indigenisation; Atomic Energy applications; Achievements of Indians in S&T.
• Plausible question stems: 1. "India's atomic energy programme has delivered significant civilian dividends beyond power generation." Discuss with reference to cancer care and radiopharmaceuticals. (GS-III, 250 words) 2. Examine the rationale and challenges of housing a tertiary cancer-care network under the Department of Atomic Energy rather than the Health Ministry. (GS-II) 3. Discuss how indigenous radioisotope and radiotherapy production strengthens India's health security and Atmanirbhar Bharat goals. (GS-III)

9. Related Topics to Study Next

• Atomic Energy Act, 1962 — statutory basis for DAE [legal underpinning].
• BARC, IGCAR, NPCIL, BRIT — DAE family of institutions.
• Ayushman Bharat — PM-JAY & Health Infrastructure Mission — complementary tertiary-care thrust.
• National Cancer Grid (NCG) — TMC-anchored network of 300+ cancer centres.
• Three-Stage Nuclear Programme — strategic context for DAE.
• Bhabhatron, AKRUTI, FOLPIK — DAE societal spinoffs.
• Lutetium-177 / PSMA therapy — global radiopharma trend.
• Cancer epidemiology in India (ICMR-NCRP) — burden data context.

10. Common Errors / Trap Areas

• HBCH/TMC come under DAE, NOT Ministry of Health & Family Welfare.
• BRIT ≠ AERB (the regulator). BRIT = isotope producer; AERB = Atomic Energy Regulatory Board.
• F-18 is cyclotron-produced; Mo-99/Lu-177 are reactor-produced — examiners swap these.
• MPMMCC is in Varanasi (UP) — not Mumbai; sometimes confused with TMH/ACTREC.
• Bhabhatron is a teletherapy machine, not a nuclear reactor or isotope.
• DAE has no Cabinet Minister — it is under the PMO; aspirants wrongly assign it to MoS S&T.